User: Guest  Login
Title:

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Document type:
Journal Article; Article
Author(s):
Park, Sophie; Hamel, Jean-François; Toma, Andrea; Kelaidi, Charikleia; Thépot, Sylvain; Campelo, Maria Diez; Santini, Valeria; Sekeres, Mikkael A; Balleari, Enrico; Kaivers, Jennifer; Sapena, Rosa; Götze, Katharina; Müller-Thomas, Catharina; Beyne-Rauzy, Odile; Stamatoullas, Aspasia; Kotsianidis, Ioannis; Komrokji, Rami; Steensma, David P; Fensterl, Jaime; Roboz, Gail J; Bernal, Teresa; Ramos, Fernando; Calabuig, Marisa; Guerci-Bresler, Agnès; Bordessoule, Dominique; Cony-Makhoul, Pascale; Cheze...     »
Abstract:
Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of secon...     »
Journal title abbreviation:
J Clin Oncol
Year:
2017
Journal volume:
35
Journal issue:
14
Pages contribution:
1591-1597
Language:
eng
Fulltext / DOI:
doi:10.1200/JCO.2016.71.3271
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/28350519
Print-ISSN:
0732-183X
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX